Ferrochelatase Inhibition as a Senolytic Strategy in Temozolomide-Treated Glioblastoma

Figure 1. Time-dependent induction of GL216 senescence by TMZ. (B) PCR analysis of the expression of senescence-associated cytokines at 24 and 48 h after TMZ treatment. *P Figure 3. Effect of FECH inhibition on GL216 cells treated with TMZ. (A) Changes in FECH expression levels in GL216 cells 24 h after TMZ treatment. (B) Viability of GL216 cells at different time points (0, 12 and 24 h) after TMZ treatment, with concurrent inhibition of FECH by DTDD. (C-D) PCR analysis of the expression of senescence-associated cytokines at 24 h after TMZ or TMZ+DTDD treatment.Figure 4. Effect of FECH inhibition on GL216 tumor-bearing mice treated with TMZ. (A) Survival rate of GL216 tumor-bearing mice treated with TMZ and DTDD. N=6. (B) Body weight changes of GL216 tumor-bearing mice treated with TMZ and DTDD. N=6.